Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer

Journal of B.U.ON.

Volumn 18, Issue 2, 2013, Pages 372-376

  Cakar, Burcu ^a   Varol, U ^a   Junushova, B ^a   Muslu, U ^a   Gursoy Oner, P ^a   Gokhan Surmeli, Z ^a   Cirak, Y ^a   Karaca, B ^a   Sezgin, C ^a   Karabulut, B ^a   Uslu, R ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Breast cancer; ER; HER 2; Ki 67; Neoadjuvant chemotherapy; PR

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; THERAPY EFFECT; TUMOR LOCALIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLECTOMY; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879574630     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-2204. (Pubitemid 46954643)
3. André T, Boni C, Navarro M et all. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
4. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008 Jul 16;(3):CD005390.
5. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-2029.
6. Schippinger W, Samonigg H, Schaberl-Moser R et al. Austrian Breast and Colorectal Cancer Study Group: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007;97:1021-1027. (Pubitemid 47587021)
7. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-271.
8. Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 2007;6:683-690. (Pubitemid 350221365)
9. Sinicrope FA, Rego RL, Foster NR et al. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res 2008;14:4128-4133.
10. Inafuku Y, Furuhata T, Tayama M et al. Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. Cancer Sci 2009;100:852-858.
11. Buhmeida A, Bendardaf R, Hilska M et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. Gastrointest Cancer 2009;40:91-97.
12. Quah HM, Chou JF, Gonen M et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008;51:503-507.
13. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806. (Pubitemid 41095169)
14. Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery 2000;127:370-376.
15. Compton CC, Fielding LP, Burgart LJ et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-994. (Pubitemid 30602039)
16. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007;99:433-441. (Pubitemid 47073566)
17. Takagawa R, Fujii S, Ohta M et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 2008;15:3433-3439.
18. Tournigand C, de Gramont A. Chemotherapy: Is adjuvant chemotherapy an option for stage II colon cancer? Nat Rev Clin Oncol 2011;8:574-576.
19. Machover D, Goldschmidt E, Chollet P et all. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-696. (Pubitemid 16114715)
20. De Gramont A, Krulik M, Cady J et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-1503.
21. André T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21:2896-2903. (Pubitemid 46621839)
22. André T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007;25:3732-3738. (Pubitemid 47372615)
23. No authors listed: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17:1356-1363.
24. O'Connor ES, Greenblatt DY, LoConte NK et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381-3388.
25. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-2943.
26. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395-3407. (Pubitemid 41103699)
27. Wu X, Zhang J, He X et al. Postoperative Adjuvant Chemotherapy for Stage II Colorectal Cancer: A Systematic Review of 12 Randomized Controlled Trials. J Gastrointest Surg 2012;16:646-655.
28. de Gramont A, Hubbard J, Shi Q et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 2010;28:460-465.
29. Sargent D, Shi Q, Yothers G et al. Adjuvant Colon Cancer End-points (ACCENT) Group: Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011;47:990-996.
30. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-1425. (Pubitemid 39429665)
31. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257. (Pubitemid 36859476)
32. Jover R, Zapater P, Castells A et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006;55:848-855. (Pubitemid 43764557)